Fortress Biotech, Inc.FBIOEarnings & Financial Report
Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.
Revenue
$14.6M
Gross Profit
$10.2M
Operating Profit
$-22.1M
Net Profit
$-12.9M
Gross Margin
69.4%
Operating Margin
-151.0%
Net Margin
-88.0%
YoY Growth
-57.9%
EPS
$-0.76
Fortress Biotech, Inc. Q3 FY2024 Financial Summary
Fortress Biotech, Inc. reported revenue of $14.6M (down 57.9% YoY) for Q3 FY2024, with a net profit of $-12.9M (down 155.0% YoY) (-88.0% margin). Cost of goods sold was $4.5M, operating expenses totaled $32.3M.
Key Financial Metrics
| Total Revenue | $14.6M |
|---|---|
| Net Profit | $-12.9M |
| Gross Margin | 69.4% |
| Operating Margin | -151.0% |
| Report Period | Q3 FY2024 |
Fortress Biotech, Inc. Annual Revenue by Year
Fortress Biotech, Inc. annual revenue history includes year-by-year totals (for example, 2025 revenue was $63.2M).
| Year | Annual Revenue |
|---|---|
| 2025 | $63.2M |
| 2024 | $57.7M |
| 2023 | $84.5M |
| 2022 | $75.7M |
Fortress Biotech, Inc. Quarterly Revenue & Net Profit History
Fortress Biotech, Inc. results over the last 8 reported quarters, including revenue, net profit and year-over-year growth.
| Quarter | Revenue | Revenue YoY | Net Profit | Net Margin |
|---|---|---|---|---|
| Q4 FY2025 | $16.1M | +6.3% | $-3.9M | -24.5% |
| Q3 FY2025 | $17.6M | +20.5% | $5.8M | 33.2% |
| Q2 FY2025 | $16.4M | +10.2% | $15.5M | 94.4% |
| Q1 FY2025 | $13.1M | +0.8% | $-10.6M | -80.6% |
| Q4 FY2024 | $15.1M | -24.2% | $-6.8M | -44.7% |
| Q3 FY2024 | $14.6M | -57.9% | $-12.9M | -88.0% |
| Q2 FY2024 | $14.9M | -14.3% | $-10.9M | -73.5% |
| Q1 FY2024 | $13.0M | +4.8% | $-15.4M | -118.3% |
Income Statement
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $13.0M | $14.9M | $14.6M | $15.1M | $13.1M | $16.4M | $17.6M | $16.1M |
| YoY Growth | 4.8% | -14.3% | -57.9% | -24.2% | 0.8% | 10.2% | 20.5% | 6.3% |
Balance Sheet
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Assets | $164.6M | $145.7M | $127.1M | $144.2M | $178.1M | $159.9M | $181.4M | $185.5M |
| Liabilities | $168.6M | $160.3M | $139.8M | $145.9M | $145.6M | $122.5M | $116.2M | $123.4M |
| Equity | $23.0M | $17.9M | $21.2M | $22.7M | $22.3M | $43.9M | $55.9M | $49.9M |
Cash Flow
| Q1 2024 | Q2 2024 | Q3 2024 | Q4 2024 | Q1 2025 | Q2 2025 | Q3 2025 | Q4 2025 | |
|---|---|---|---|---|---|---|---|---|
| Operating CF | $-25.4M | $-21.8M | $-20.1M | $-12.9M | $-19.6M | $-27.6M | $-6.1M | $-12.5M |